Compare ORCL & LLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORCL | LLY |
|---|---|---|
| Founded | 1977 | 1876 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 423.1B | 818.6B |
| IPO Year | 2005 | 2007 |
| Metric | ORCL | LLY |
|---|---|---|
| Price | $177.35 | $903.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 35 | 19 |
| Target Price | $261.29 | ★ $1,217.79 |
| AVG Volume (30 Days) | ★ 20.6M | 2.3M |
| Earning Date | 03-10-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.18% | 0.76% |
| EPS Growth | 16.98 | ★ 95.99 |
| EPS | 4.38 | ★ 22.95 |
| Revenue | $57,399,000,000.00 | ★ $65,179,000,000.00 |
| Revenue This Year | $19.51 | $26.98 |
| Revenue Next Year | $32.08 | $15.83 |
| P/E Ratio | ★ $38.74 | $39.56 |
| Revenue Growth | 8.38 | ★ 44.70 |
| 52 Week Low | $121.24 | $623.78 |
| 52 Week High | $345.72 | $1,133.95 |
| Indicator | ORCL | LLY |
|---|---|---|
| Relative Strength Index (RSI) | 69.98 | 39.64 |
| Support Level | $173.84 | $877.11 |
| Resistance Level | $237.98 | $1,102.49 |
| Average True Range (ATR) | 6.66 | 27.65 |
| MACD | 3.93 | 1.68 |
| Stochastic Oscillator | 93.87 | 25.81 |
Oracle provides enterprise applications and infrastructure offerings through a variety of flexible IT deployment models, including on-premises, cloud-based, and hybrid. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system, which is commonly used by the world's largest companies for high-volume online transaction processing workloads. Besides databases, Oracle also sells enterprise resource planning platforms and cloud infrastructure that play an increasingly important role in large language model training and inferencing.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.